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Introduction
On 4th July 2017 the UK Chief Medical Officer (CMO), 
Dame Sally Davies, published her 2016 Annual Report, 
Generation Genome, which focused on her vision to inte-
grate genomics into the UK’s national healthcare system 
(Davies 2017). The final Chapter of her report explores how 
this vision, which she coined the ‘genomic dream’, should be 
implemented in an ethically and socially acceptable manner. 
It stresses the need for an appropriate ethical governance 
system that can be trusted by patients; responsible health 
professionals which uphold this trust; clear, open protection, 
and privacy of genomic data; and best practice approaches 
to patient consent (Lucassen et al. 2017). In this paper we 
explore how some of these ethical issues are beginning to be 
addressed in practice. Specifically we explore how the UK’s 
100,000 Genomes Project (100 kGP)—the catalyst of this 
‘genomic dream’, and catalyst for bringing genomics into the 
UK National Health Service (NHS), is negotiating some of 
these ethical concerns.
The UK’s 100 kGP, promoted and delivered by Genomics 
England Limited (GEL), is an innovative venture aiming to 
sequence 100,000 genomes from NHS patients who have a 
rare disease, cancer, or an infectious disease (Gov.uk 2012). 
Launched in 2012 by ex-UK Prime Minister David Cam-
eron, and due to be completed by 2018,1 its ambition reflects 
Abstract The UK Chief Medical Officer’s 2016 Annual 
Report, Generation Genome, focused on a vision to fully 
integrate genomics into all aspects of the UK’s National 
Health Service (NHS). This process of integration, which 
has now already begun, raises a wide range of social and 
ethical concerns, many of which were discussed in the 
final Chapter of the report. This paper explores how the 
UK’s 100,000 Genomes Project (100 kGP)—the catalyst 
for Generation Genome, and for bringing genomics into 
the NHS—is negotiating these ethical concerns. The UK’s 
100 kGP, promoted and delivered by Genomics England 
Limited (GEL), is an innovative venture aiming to sequence 
100,000 genomes from NHS patients who have a rare dis-
ease, cancer, or an infectious disease. GEL has emphasised 
the importance of ethical governance and decision-making. 
However, some sociological critique argues that biomedical/
technological organisations presenting themselves as ‘ethi-
cal’ entities do not necessarily reflect a space within which 
moral thinking occurs. Rather, the ‘ethical work’ conducted 
(and displayed) by organisations is more strategic, relating to 
the politics of the organisation and the need to build public 
confidence. We set out to explore whether GEL’s ethical 
framework was reflective of this critique, and what this tells 
us more broadly about how genomics is being integrated 
into the NHS in response to the ethical and social concerns 
raised in Generation Genome. We do this by drawing on a 
 * Gabrielle Natalie Samuel 
 gabbysamuel@gmail.com
 Bobbie Farsides 
 b.farsides@bsms.ac.uk
1 Brighton and Sussex Medical School, University of Sussex, 
Falmer BN1 9PX, UK
 G. N. Samuel, B. Farsides 
1 3
that of the CMO’s report (and indeed Dame Sally Davies 
sits on GEL’s board)—to incentivise the transformation of 
clinical care so that genome sequencing eventually becomes 
routine diagnostic practice within the NHS. It also has a 
research-focused goal to provide genome data for scientific 
discovery and future patient benefit.2 The NHS has been 
given responsibility for recruiting and consenting patients to 
the project, and collecting patients’ DNA samples for later 
clinical and research analysis; GEL’s responsibilities lie with 
procuring the genome sequencing, and established a bio-
repository for data storage and clinical/research analysis by 
a range of commercial, clinical and academic actors.3,4 It is 
foreseen that by the completion of the project an NHS infra-
structure for genomic medicine, both in terms of clinical and 
research practice, will have been established and ‘generation 
genome’ will be underway.
Unsurprisingly, 100 kGP raises ethical questions aligned 
with those highlighted in the CMO’s annual report, includ-
ing how best to consent patients to the project (in terms of 
dealing with additional findings,5 confidentiality, and patient 
expectations); how best to ensure data protection and pri-
vacy; how to engage/inform the public about the venture; 
how to ensure equitable access to care; and how best to inter-
act with commercial companies wishing to access genomic 
data for research; as well as important questions less spoken 
about in the CMO’s report around the value and usefulness 
of incorporating genomics into healthcare more broadly.
Given the range of ethical concerns associated with 
100 kGP, and the venture’s importance as a key initiator 
of integrating genomics into the NHS, GEL has made an 
open commitment to act ethically in terms of its policies and 
practice. Drawing on the contemporary belief that engag-
ing the public is synonymous with ethical decision-making 
(Irwin 2006), it has a strong public engagement strategy 
comprising a resourceful website and a wide range of events 
to both inform the public and also to listen to their opinions 
about how the project is un-folding in practice6 (Samuel 
and Farsides 2017a, b). Furthermore, a bioethicist sits as 
a non-executive member on GEL’s board to emphasise the 
ethical dimensions of policy decision-making; and within 
the organisation GEL has a team of two individuals who are 
responsible for ensuring commitment to ethical policymak-
ing and adherence to ethical regulations in practice.
Within the range of committees established by GEL to 
help with the formulation of policy and strategies, those with 
a particular focus on ‘ethics’ include the participant panel 
(which ensures patients and the public are involved in deci-
sion-making), the public engagement committee (respon-
sible for public engagement activities), and the data access 
committee (controls access to the data and samples collected 
within the project). Finally, in line with the reasoning that 
ethics committees associated with large, complex biomedi-
cal organisations allow for concurrent, practical ethical 
questioning of projects, GEL has also established an inde-
pendent Ethics Advisory Committee (EAC). The committee 
meets around four times a year to discuss and advise on any 
pertinent issues emerging from the venture and is compro-
mised of individuals from clinical and research genetics, 
policy, law, ethics, nursing, and patient/ public representa-
tives. Three EAC sub-committees give specific advice on 
the areas of the consent process, issues of equity of access 
to care/research, and issues of legacy and ethical manage-
ment once 100 kGP finishes. Given all this, and in line with 
the CMO’s report to ensure the consideration of ethical and 
social issues when bringing genomics into healthcare, there 
is no question that GEL’s framework has been established to 
accommodate, and even emphasise the importance of ethi-
cal decision-making and governance when developing the 
organisation’s policy and practice.7
GEL’s commitment to ethics reflects not only those calls 
made within the CMO’s report to bring genomics into the 
NHS in an ethically acceptable manner, but also the contem-
porary landscape of science governance more generally, in 
which increasing attention is being paid to ethical issues at 
the policy level. In fact, Bogner and Menz claim that ‘eth-
ics has become the dominant discourse [of science govern-
ance]. In the course of this ‘‘ethical turn’’ national ethics 
councils [have been] set up throughout Europe and in the 
United States to advice politics in ethically controversial 
issues’ (p. 888) and ethics is ‘now the relevant discourse of 
reflection in nearly all areas of society’ (Bogner and Menz 
2010, p.892).
The widespread adoption of this ‘ethical turn’ has led 
to a new level of sociological critique, where it has been 
argued that biomedical or biotechnological organisations 
presenting themselves as ‘ethical’ entities do not necessarily 
2 For more of a discussion about the clinical/research hybrid nature 
of GEL, see Dheensa et al. The research and clinical practice distinc-
tion in genomic medicine and the 100,000 genomes project: time for a 
new framework? Forthcoming.
3 https://quarterly.blog.gov.uk/2014/01/30/100000-genomes/.
4 The genomes data is being stored in a bio-repository. At present 
GEL maintains ownership of the genomes data, and access is on a 
‘borrowing’ basis. There is uncertainty about what will happen to this 
data post-project.
5 Findings not related to the reason for the test, for example, risks for 
hereditary cancers that are amenable to risk-reducing interventions 
but which are unrelated to the presenting condition.
6 http://www.genomicsengland.co.uk/about-genomics-england/.
7 This was deemed especially important in light of the public back-
lash towards previous ventures that involved the sharing of health 
data, for example care.data (Carter et al. 2015; Sterckx et al. 2016).
1 Originally 2017, but extended to 2018 due to challenges with 
recruitment.
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reflect a space within which moral thinking occurs—espe-
cially where organisations are politically incentivised, as is 
the case for GEL. Rather, the ‘ethical work’ conducted (and 
displayed) by organisations is more strategic such that the 
moral messaging relates to the politics of the organisation 
(Petersen 2005; Hoeyer 2012), with the ‘ethical presence’ 
within the company being mostly about building public con-
fidence and legitimising the organisation (Jasanoff 2005).8 
As Hoeyer notes in relation to biobanking;
Ethics has left the philosophical chamber and become 
a parameter of competition among researchers and 
commercial stakeholders. When a Swedish company, 
UmanGenomics, sought for venture capital, it ben-
efited from having been promoted in Nature and Sci-
ence as resting on a more robust ‘ethics model’ than 
the Icelandic company, deCODE. The point is that the 
change in scale necessitates new forms of maneuvering 
in relation to potential public opposition and, indeed, 
proactive ‘ethics work’ has become a prominent fea-
ture of large-scale biobanking.…as ethics turns into 
a…mode of regulation, the word as such gradually 
changes its meaning (Hoeyer 2012, p.212).
In fact, say Hoyer and Tutton, the term ‘ethics’ has gained 
a specific institutionalised purpose in ‘demonstrating that 
ethical problems are attended to’ (Hoeyer and Tutton 2005, 
p. 386).
Moreover, critics have complained that the ‘ethical turn’ 
can constrict, ‘close’ or thin ethical discourse to a consid-
eration of only formalised or principled notions of concern 
(such as, consent, autonomy, privacy); to only notions 
of concern that can be seen to be reasonably negotiated 
(Petersen 2005; Strassnig 2008; Hilgartner et al. 2016); or 
to singular discourses which de-emphasise an ‘ethos of con-
troversies’ (Poort et al. 2013). This, say scholars, leaves lit-
tle room for integration of more social, personal or cultural 
aspects of ethics, or moral thinking more broadly.
Applying this critique to GEL is concerning. It would 
mean that whilst the CMO’s report has called for not only 
patient/public trust to be built, but also upheld, the establish-
ment of GEL’s ethical framework may only be responding to 
the former. This is because whilst it would give the impres-
sion of strong ethical governance, this would only serve a 
strategic purpose rather than applying the moral thinking 
which patients/public are expecting, as well as trusting GEL 
to ensue. This could then have implications more broadly, 
since if respect for patients/public is not upheld at this stage, 
trust in the Generation Genome venture, and in the value 
of bringing genomics into the NHS as a research-clinical 
framework moving forward, could be eroded.
We therefore wanted to explore GEL’s ethical framework, 
especially the discussions conducted within the EAC, to 
determine if this was the case, and whether the ethical dis-
course within GEL could be described as ‘thin’ or ‘closed’. 
We conducted 20 interviews with those working at or associ-
ated with GEL—including a large proportion of individuals 
who sit on the EAC—to explore the nature and role of their 
ethical discussions within GEL.
Methods
Identifying participants
In order to contact those working at or associated with 
GEL, we sought permission from Board Member and EAC 
Chair, Professor Mike Parker, After viewing and sharing the 
project’s proposed rationale and methodology with GEL, 
Professor Mike Parker granted permission for the project to 
proceed. First author, GS, spoke with Head of Ethics, Laura 
Riley, about who it would be best to interview via a conveni-
ence sample to ensure a full range of opinions, stakeholders 
and institutions were garnered about 100 kGP and GEL.
Recruitment
Potential respondents were recruited in summer 2016, at 
the approximate halfway mark through the 100 kGP. Invita-
tions requesting participation, including participant informa-
tion sheets, were emailed to individuals associated with, or 
those who worked for GEL, including: GEL staff members 
(plus those involved in public engagement and the project’s 
evaluation); GEL board members; EAC members; and rep-
resentatives from the Department of Health, Public Health 
England, NHS England, and Genomics Medicine Centres 
(GMCs).9 Two follow up emails were sent to non-responding 
individuals.
20 semi-structured interviews were conducted either by 
telephone or face-to-face (at a location chosen by the partici-
pant). Interviews lasted between 30 and 105 min and were 
recorded. The interview schedule was broad, asking partici-
pants about their background and role with 100 kGP; their 
views on the project; its benefits (present and potential) and 
8 Interestingly, Levitt and Weldon’s research on genetic databases 
suggest that having a ‘public ethics’ does not serve its purpose of 
gaining trust: ‘it seems that public consultation and the language of 
openness and transparency may not be sufficient to establish trust in 
the governance of genetic databases’ (Levitt and Weldon 2005, p. 
311).
9 There are 13 NHS GMCs throughout the UK, each of which are 
centres of genomics excellence. They are responsible for delivering 
the genomes project in terms of patient recruitment and consent; and 
DNA collection, extraction, and transport for sequencing.
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drawbacks; and on the project’s ethics and public engage-
ment strategy. Interviews were transcribed either by GS or 
by external transcribers. All above categories of individuals 
were represented in the interviews (exact numbers not pro-
vided for confidentiality).
Neither Mike Parker, Laura Riley, nor GEL had any 
knowledge of who responded to the recruitment emails (and 
hence who participated in the project). They also had no 
input into the project design, interview questions which were 
asked, or the analysis of findings.
Analysis
Analysis (or coding) (Corbin and Strauss 2008) of inter-
view data was approached using inductive reasoning based 
on two inter-linked rounds: overview analysis and detailed 
analysis. Overview analysis consisted of memo-making and 
broad coding. Extensive memo-making was employed by GS 
directly after each interview. Broad coding involved scan-
ning the interview transcripts for relevant ideas and themes. 
Emerging themes identified from memo-taking/broad cod-
ing were discussed in detail with second author, BF and it 
was these discussions which informed early analysis of the 
data. Once themes emerged from these discussions, detailed 
analysis of the full transcripts occurred line-by-line by first 
author, GS, using NVivo software.
Findings
GEL’s ethical framework and ‘commodifying’ ethics
GEL’s rationale for implementing an ethical framework was 
perceived to be related to the extrinsic need to garner public 
support for the project (Tutton et al. 2004; Williams and 
Schroeder 2004; Samuel and Farsides 2017a) and nearly all 
interviewees spoke about the ethical framework constructed 
by the organisation as value-adding in terms of gaining pub-
lic trust for the venture: ‘I think it has been clear before 
GEL was established in the setup phase that it was going 
to be important for the success of the project for there to 
be a clear ethical framework that carried public confidence 
with it’ (interviewee 10). Indeed, the need to be seen to be 
acting ethically was important to avoid the project’s fail-
ure: ‘they’re very important [being seen to be dealing with 
ethical issues]…if we loose the trust of the public then the 
project will not only not be a success but is likely to fail’ 
(interviewee 13). In particular, the visibility of the EAC was 
perceived as vital to giving patients a reassurance that ethi-
cal issues were being handled appropriately (Irwin 2006): 
‘it’s easier when you work with patients saying absolutely 
there’s an ethics board associated with the project, discuss-
ing the issues that patients are bringing up. So I think it’s 
added validity and credibility’ (interviewee 11). Being seen 
to be ethical was in fact a tangible commodity for GEL—
perceived to add value to the organisation’s status scientifi-
cally, clinically and ethically, and one whose very presence 
could be exchanged as ‘currency’ for public support and 
trust.10
In positive terms ‘ethics’ can be seen as a valuable com-
modity within a context where the culture emphasises the 
importance of accountability, openness and good ethical 
conduct. However, a more cynical interpretation could pre-
sent ethics and GEL’s establishment of an ethical frame-
work—and particularly its ‘visible’ EAC—as merely 
‘window dressing’ the company with a ‘public-facing’ 
ethics—the purpose being to ‘sell’ an image that appears 
to prioritise consideration of ethical issues rather than nec-
essarily addressing them. A more nuanced position might 
hold that this commodification of ethics is just one-half of 
a dual-functioning ethical framework—a framework which 
needs to, on the one hand, be seen to be ethical in terms of 
form and function, and on the other, actually be ethical in 
terms of results. Within this latter perspective, the ethical 
framework—and especially the EAC—whilst convened to 
promote GEL as an ethical organisation, creates a secure 
space in which a group of individuals can think carefully 
about ethical issues and pave the way for productive ethi-
cal discussion (Moore 2010). To provide insight into which 
model resonates, below we explore GEL interviewees’ views 
about ethical issues discussed within GEL and the EAC.
The dual function of ethics: being a ‘commodity’ 
and ‘being ethical’
Unsurprisingly, all interviewees expressed an intrinsic desire 
for GEL to make ethical decisions in practice, highlighting 
the importance placed on the organisation to ‘act ethically’ 
alongside the need to appear ethical: ‘it’s important that 
we’re not just ethical but that we’re seen to be ethical as well 
to provide public confidence and that’s incredibly important’ 
(interviewee 2). For interviewee 2, and others, it would be: 
‘very disappointing if that [being seen to be ethical] was the 
only purpose that the ethical focus had. I think that that is 
a necessity of what we need for public engagement but the 
real important stuff is the ethical questions that we keep on 
facing as we look at how we address this’.
In terms of the types of ethical considerations discussed 
within the EAC, the first point to note is that, as has been 
documented in terms of other biobank-style initiatives (Wal-
lace 2005), there was no perceived need to question the 
underlying value or usefulness of the genomics programme 
10 Others have also talked about notions of “currency” in the moral 
economy of biotechnology (Petersen 2015).
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within the NHS (a point we return to in the discussion). 
Rather, interviewees reported discussions were focused on 
the ethical issues associated with rolling out the venture into 
practice, and concerns about a range of issues already exten-
sively discussed in the literature, such as how to consent 
patients; how to ensure that data is secure and confidential; 
how to interact with commercial companies; how to provide 
equitable access; and how to handle the clinical issue of 
additional findings. These discussions were perceived to be 
where real ethical debates and decision-making occurred, 
and were seen to be disconnected from the more strategic 
ethical work used to ‘window dress’ the organisation: ‘I do 
recognise that there’s probably a disconnect between what 
actually is presented as the ethics issues and what actually 
could be recognised to be the ethics issues’ (interviewee 8). 
We provide two examples of this disconnect to highlight the 
different types of ethical work which were being conducted 
at GEL in terms of issues of privacy, commercial interaction 
and consent.
First, GEL interviewees did not always see those issues 
which they gave high public prominence to on their web-
sites and during public discussions11 i.e., those related to 
privacy, commercial interaction and data security as the 
only pertinent issues for them to discuss and reflect on.12 
Rather, they perceived that whilst some evidence suggests 
the public attribute more importance to protecting privacy 
than maximising new healthcare benefits in terms of genetic 
biobanks (Critchley et al. 2016), this was not the case for 
patients, whose values were more shaped by the desire to 
get well/gain a diagnosis. As interviewee 16 noted, it was 
important to ensure that whist public ethics revolved around 
broader discussions of privacy, when thinking about GEL’s 
decision-making the need for a consideration of patients’ 
social, political and cultural contexts is important, and poli-
cies ‘must be within the reasonable bounds of ethics—this 
must be determined by the patients who are affected by these 
diseases and not by entirely well intended but unaffected 
people who aren’t going through the experience they are’. 
In light of this, GEL created a series of online interviews 
with families who have taken part in 100 kGP13 as a way 
to highlight patient views and beliefs about the project, and 
to alert GEL to any concerns families may have about their 
experiences, or about the way the project is unfolding. One 
such interviewee stated that;
Some people worry that their data will be exposed…or 
might be used by commercial companies, as far as I’m 
concerned commercial companies doesn’t [sic] bother 
me as long as they make benefit to humanity [sic] to 
people like…my child14,15
Such patient perspectives—where health benefits are 
prioritised over a consideration of (for example) concerns 
about interacting with commercial companies—need to be 
considered alongside other viewpoints, such as those of the 
public, who, whilst in good health, may be more concerned 
about privacy and commercial interaction than immediate 
health benefits.
A second example of the disconnect between public and 
inward facing ethics emerged from interviewees’ discussions 
about consent: GEL’s presentation of ethics on its public-
facing website, particularly in terms of the slick download-
able consent form and the impression that is created of ethi-
cal work having been done, stood in contrast to interviewees’ 
discussions about the messiness, uncertainty and far from 
finished issues facing patients when trying to complete the 
consent form in practice:
That consent form all looks very slick, but it takes a 
nurse or a clinician over an hour to go through that 
consent form with the participant. If you think that 
they have just been diagnosed with cancer for exam-
ple, are you in that space of mind where you want to 
be asked all of those questions and go through a very 
lengthy consent form? I can almost imagine being sat 
there with a couple of kids around me who are crying 
and upset and want to go home, but you’re trying to 
fill in a consent form.
Indeed, EAC interviewees in particular spoke at great 
length about the range of concerns still troubling them in 
terms of developing a best practice model for consent, which 
rather than completed, was considered as an ongoing itera-
tive process between themselves, patients and the research 
ethics committee who had provided ethical approval for the 
genomes project. The iterative approach is now visible in 
the participant information sheets and consent forms, which 
have recently been re-drafted in response to patient feed-
back. This includes changes to their layout, a simplification 
of language, and the addition of illustrative diagrams.
These examples suggest that, in comparison to public 
facing ethics, the ethical work occurring within the EAC 
(and within GEL more broadly) recognises the messiness 
11 We attended several public debates, and the privacy issue was a 
predominant discussion point.
12 http://www.genomicsengland.co.uk/about-genomics-england/.
13 https://www.genomicsengland.co.uk/taking-part/participant-sto-
ries/.
14 https://www.genomicsengland.co.uk/.
15 We have discussed elsewhere that given these videos often display 
families who are positive about the project or have received a posi-
tive result, GEL must be vigilant that they do not act as a conduit for 
promoting high expectations about the project, which could in turn 
raise false hope for families about what 100kGP is able to achieve in 
clinical practice.
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of implementing 100 kGP into practice, and is attuned to 
the needs and experiences of patients. Though there was 
definitely some cause for concern: the need to appear ethi-
cal was perceived by some interviewees to overshadow the 
inward facing ethics. As interviewee 18 stressed: ‘I think our 
academic, our research bodies, our large communities, our 
local authorities are far more concerned with telling people 
about governance, structures, who sits on what committee 
and so on as opposed to what it is we’re going to do by 
when’. Moreover, the ethical work being conducted within 
GEL, and specifically the EAC, resonates with similar con-
siderations previously discussed in conversations within 
biobank organisations and their ethical advisory committees. 
Here several sociological scholars questioned their value, 
arguing that whilst they do consider the consent process 
and a range of patient views, they frame ethics too narrowly 
using only formalised notions of consent, autonomy, and pri-
vacy (Petersen 2005) and fail to contextualise ethics within 
everyday practice.
There was some evidence of this at GEL, for example in 
their prioritising the importance of the consent process as 
a central formalised ‘ethical’ aim of the organisation (“to 
create an ethical and transparent programme based on 
consent”). Moreover, it is well known that decision-making 
during the consent process is often less related to the infor-
mation provided (which may not even be read/remembered 
by patients/participants), and more about patient/participants 
personal, cultural and social-economic circumstances; their 
pre-formed expectations about the research; and impor-
tantly, the trusting and communicative relationship built 
between themselves and researcher/clinician (Hoeyer and 
Lynoe 2006; Hallowell et al. 2010; Grady 2015; Samuel 
et al. 2017). Whilst GEL aimed to be open and transparent 
about the project and its expectations, rather than reflecting 
on the decision-making process in its social context, and the 
role of the consent process more broadly in terms of deci-
sion-making, GEL took the approach of providing extensive 
information about the project during the consent process as 
a proxy (albeit one of many) for acting ethically.
The perceived value of the ethics advisory committee
Interviewees had different perceptions about the value of any 
of the discussions they had about the ethics associated with 
100 kGP within the EAC, and the value of the EAC more 
broadly in terms of how much their discussions influenced 
GEL’s policies and practices. Some interviewees viewed the 
EAC’s role as valuable in raising ethical issues since, ‘a lot 
of the them [ethical issues] have come up for at least some 
sort of discussion in the advisory group, so I think there’s 
a forum in which they can be raised, and are’ (interviewee 
1). For others, the types of discussions being had within 
the EAC missed certain ethical perspectives. Reflecting on 
another organisation’s ethics committee, interviewee 5 com-
mented that:
The good thing about that committee was they had 
a good patient rep side…It was a mixture of people 
who are rare disease patients who had a certain model 
of it, and those who were from these disability rights 
background, you had both…And I think sometimes, 
that’s not what we’re getting in the 100,000 Genomes 
Project…we have the medical model much more than 
we have had the disability model.
Moreover, the lack of consensus reached during EAC dis-
cussions, and the fact that policy-making was seen to take 
place elsewhere, meant the committee was not always per-
ceived to serve any useful function:16
[My role is to] turn up at meetings three times a year. 
I mean its very interesting, I basically don’t think we 
serve a function. I really am not convinced that we 
serve any useful function. We discuss things, the peo-
ple around the table are very nice, we say things. And 
I’m sure they take notice of the odd things that we say 
because it is a very competent group of knowledge-
able individuals. But I think all the decisions are taken 
elsewhere (interviewee 3).
Interviewees explained how the EAC’s Chair, who 
was well-respected in the field and had decades of experi-
ence (including the social and ethical contexts of genom-
ics), had mapped the ethical issues before the project’s 
commencement:
[The Chair] has been involved in the ethics under-
pinning genetics applied to patients for, well, 
almost…20 years. So this hasn’t come out of the blue. 
It’s been evolving gradually and thoughtfully and he’s 
been thinking quite seriously about what all these 
issues are for a long period of time (interviewee 7).
Because of this, and because the Chair also sat on GEL’s 
board, interviewees felt that the project would probably man-
age very well without the EAC: ‘I think the project could 
run very well without it [the EAC], with a few people on 
the executive like [the Chair] who has a lot of integrity’ 
(interviewee 11).
Others disagreed, insisting that the EAC was only ever 
supposed to be an advisory group [‘we don’t have any exec-
utive function… ours is advisory up the GEL food chain’ 
(interviewee 6)], and that its function emanated from acting 
16 In contrast, Bogner and Wetz note how ethics is in fact distin-
guished by a lack of consensus, and this aspect is viewed as its 
worth—bringing diverse viewpoints to policy deliberation (Bogner 
and Menz 2010).
Public trust and ‘ethics review’ as a commodity: the case of Genomics England Limited and the…
1 3
as a sounding board for the Chair, to give confidence to him 
when bringing ethical dimensions to the policy-making 
table:
I have occasionally not been able to make a particular 
meeting…I come along to the next one and it doesn’t 
feel like I’ve missed anything…On the other hand, it 
may well be that [the Chair] doesn’t feel that way, and 
he actually needs the sounding board, and he needs the 
authority of having taken it to the committee, to then 
go back to the board of Genomics England and say 
well, our advice is this (interviewee 13).
Discussion
We have explored how ethical issues associated with 
100 kGP are being negotiated by GEL as it moves towards 
establishing genomic medicine as part of NHS infrastruc-
ture—an infrastructure supported and promoted by the 2016 
CMO Report Generation Genome. We have shown that the 
public presentation of GEL’s ethical framework has acted as 
a commodity to be exchanged for public trust, and to legiti-
mise the organisation to ensure support for its activities, and 
the move towards a genomic NHS. The public presentation 
of ethics gives the impression that ethics is ‘attended to’ 
and resolved—an impression which critics may construe as 
being more about fulfilling a policy agenda than providing a 
space for any real philosophical analysis (Hoeyer and Tutton 
2005). As Hoeyer and Tutton note, presenting ethics in this 
way gives a false impression of what ethics really amounts 
to in practice and allows for the fact that ‘no matter how 
ambitious or controversial, biomedical research is then able 
to progress’ (Hoeyer and Tutton 2005, p. 386). Moreover, 
commodifying ethics has also been argued to prioritise for-
malised ethical issues (e.g. privacy, consent and autonomy) 
at the expense of more everyday patient concerns (Petersen 
2005; Strassnig 2008).
We have also shown that GEL’s ethical framework, and 
in particular the EAC, provides a genuine space for ethical 
discussion. This ethical discussion sat in contrast with the 
public presentation of ethics, illustrated the messiness of 
ethical-decision making in practice, and demonstrated GEL’s 
attentiveness to patient and family members experiences and 
social setting. However, there were some areas of concern. 
First, relating to the relevance and purpose of the EAC dis-
cussions: having discussions was perceived as worthy, but 
there was a sense that the debates had during EAC meet-
ings may have little relevance to policy and practice. Sec-
ond, relating to the medicalised model adopted during EAC 
discussions: as one interviewee noted, the disability model 
was lacking in the EAC, which, if included, could have 
emphasised an interesting discussion about the relevance 
and usefulness of genomics within the NHS. However, the 
dual role for the EAC Chair as a GEL board member was 
perceived as beneficial and meant that a link was provided 
between EAC discussions and policy decision-making prac-
tice. And whilst some interviewees were hesitant, the hope 
was that this link would allow the former to influence the lat-
ter. Though we note that more research would be needed to 
determine specifically how much dialogue has moved from 
the EAC to the policy level, and stress that this research is 
imperative since, with patients placing so much trust in the 
project, GEL has an ethical responsibility to be mindful of 
what this ‘trust’ means,17 and ensure that the venture does 
not only gain public trust but that it upholds it (and they are 
not only having inward ethical discussions, but that these 
discussions are listened to and acted upon by policy makers). 
As the Chief Medical Officer’s report states: ‘the ability of 
the NHS to show that it can be trusted on these [aforemen-
tioned ethical] issues will be an important foundation for the 
reasonableness of the new social contract [between the NHS 
and patients with respect to genomics] that we [the authors 
of the Chapter] propose’ (Davies 2017, Chap. 16 p. 11). A 
similar point is also emphasied by Woolley and colleagues, 
who note that ‘in order to merit and garner trust, guardians 
of citizens’ health data ought to ensure that they respect the 
values of the people who are expected to trust them with 
their data’ (Woolley et al. 2016) and Dame Fiona Caldicott 
(National Data Guardian),18 who notes that there should be 
‘no surprises’ to patients about how their genomic data has 
been used.
Indeed, there was an impression that this trust was upheld, 
and interviewees perceived GEL to be attentive to the ethical 
and social issues related to 100 kGP. However, there were 
at least some serious concerns from interviewees that GEL 
was prioritising the need to be viewed as ethical rather than 
actually being ethical. A discrepancy also emerged as we 
moved away from how GEL negotiated fomalised ethical 
issues to how such formalised issues were being questioned. 
This was most clearly evidenced with relation to consent. 
Here, GEL interviewees’ concerns amounted to achieving 
a process which best-informed patients about 100 kGP in a 
clear and understandable way, taking into account patient/
participant views, along with their social setting. Less fre-
quently discussed during interviews were questions about 
the usefulness or appropriateness of the consent process. 
Other ethical questioning seemed to also be missing, with 
17 We have argued elsewhere that respecting trust should be formal-
ised and considered on par with other ethical obligations such as pro-
viding information (Samuel et al. 2017).
18 https://www.gov.uk/government/speeches/protecting-con-
fidentiality-and-improving-care-not-a-zero-sum-game?utm_
content=buffere0b53&utm_medium=social&utm_source=twitter.
com&utm_campaign=buffer.
 G. N. Samuel, B. Farsides 
1 3
GEL interviewees noting a limited ethical discussion regard-
ing 100 kGP’s moral worth and its scientific validity and 
applicability—a point also missing in the CMO Report. We 
explore these missing discussions below.
It has been argued that space should be made for debates 
about a biotechnology’s scientific validity or applicability 
(i.e., whether the technology is fit for function) within an 
organisation’s practice (such as within an ethics advisory 
committee), otherwise, implications drawn from any ethi-
cal debate would rely on incorrect underlying assumptions 
about the science itself. As Wallace and Barbour argue in 
terms of biobanking, removing the debate about whether the 
science can offer anything useful in terms of patient ben-
efit invalidates any proceeding ethical discussion (Barbour 
2003; Wallace 2005). Hoeyer and Tutton (Hoeyer and Tutton 
2005) explain why organisations may be hesitant to have this 
debate, since any further discussion would;
Undermine [the ethics advisory committee’s] very 
mandate; their own ‘space of action’ would dissolve 
if they were to conclude that the money intended for 
UK Biobank would be better spent on public health 
measures of another kind. To confirm their own space 
of action, such ethics advisory boards must confirm 
the importance of research, and limit themselves to 
identifying the ways it should continue (p. 393).
Whilst this is a point well made, we suggest, as we have 
done elsewhere (Samuel and Farsides 2017a) that it is not 
the place for GEL to debate the ethical dimensions of their 
very existence. It has passed the point where it would be 
productive for GEL to demonstrate their worth and/or defend 
their existence in terms of abstract argument. Rather the time 
has come to demonstrate how they will contribute to health 
in a scientifically, clinically and ethically robust manner. 
Discussions about whether or not technologies should be 
implemented into practice (what has been called the ‘ethics 
of innovation’ (Strassnig 2008), or the ‘bioethics of innova-
tion’ (Lipworth and Axler 2016)) are a vital aspect of ethical 
discussion—and an aspect in desperate need of attention. 
But the place to have such discussions is not necessarily 
within the organisation which has been given the political 
green light to go ahead—an organisation which now needs 
to put its efforts into negotiating the ethical issues the pro-
ject raises, and under a huge time constraint imposed by 
the time-limited political expectations (Samuel and Farsides 
2017b). Rather, what is needed is a discussion about who 
should have the responsibility for these wider debates more 
broadly. This might become increasingly difficult in the 
wake of the CMO 2016 Report because, by driving Genera-
tion Genome at such a pace, this Report leaves little room 
for broader stakeholder and public discussions which may 
question the appropriateness of genomic technologies within 
the healthcare system.
We can also apply a similar argument to the notion of 
consent: a number of practical reasons made it extremely 
difficult, logistically, for GEL to question the notion of pro-
viding anything other than an information-focussed consent 
process as the primary emphasis of patient decision-mak-
ing. These included the pace of the project, the need to get 
participants recruited, and the consequent time restrictions 
attached to this, leaving limited time for any form of discus-
sion of different ways to approach consent. Furthermore, 
GEL’s decision to submit 100 kGP for ethical approval 
meant that research ethics committee members—adher-
ing to traditional notions of needing to provide all relevant 
information in the participant information sheet and consent 
form—placed restrictions on the form’s content. Whilst all 
of these factors made it difficult to question the notion of 
the consent process more broadly, GEL did have strategies 
in place to ensure consent was as patient-led as possible, 
that GEL maintained open communication channels with 
patients and the public, and provided a strong ethical gov-
ernance structure for the whole organisation. This meant 
that the process did not just act as a proxy for good ethi-
cal practice, but as one ‘important component of an ethics 
ecosystem’—something suggested as crucial by the CMO 
Report’s ethical guidance (Davies 2017, Chap. 16 p. 5). 
Having said this, it still leaves questions remaining about 
how best to ensure public/patient interests and desires are 
adequately met as we move at a fast-pace towards a new 
form of genomic healthcare, and whose responsibility it is 
to find the time and space to explore these questions about 
the usefulness and purpose of consent in an era of genomics, 
and apply recommendations of best-practice.
Concluding remarks
GEL’s ethical framework, whilst a commodity established 
to be exchanged for patient and public trust, seems to offer 
value in terms of ethical decision-making—conforming to 
organisational notions of ethical practice, as well as con-
sidering, to some extent, more everyday issues which may 
affect patients. Though we note it is important that GEL (and 
in time, as Generation Genome unfolds, the NHS) remains 
vigilant to ensure that its desire to ‘window dress’ ethical 
issues to gain public support does not overshadow the need 
to be ethical. We also note that whilst GEL stopped short of 
questioning the value of 100 kGP, or moving beyond for-
malised notions and discussions of ethical practice, this is 
ethically justifiable. Nevertheless, again, we emphasise the 
importance of having these types of discussions elsewhere, 
and pose questions about upon whom this responsibility 
should fall as the UK moves towards Generation Genome, 
and as genomics becomes more integrated within the UK 
NHS. Without these discussions, debate around genomics 
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within UK healthcare will remain only within organisational 
settings, the remit of which (we have argued in this paper) 
justifiably is much narrower and more fomalised. In which 
case, there is a risk that the discussions about genomics 
within the NHS will fall into the trap of being too ‘closed’ 
and lacking in an ‘ethos of controversies’ (Petersen 2005; 
Strassnig 2008; Poort et al. 2013; Hilgartner et al. 2016).
Limitations
Our findings are based on interviewees’ perceptions of ethi-
cal decision-making within GEL and give a broad picture of 
GEL’s practices with relation to ethics, providing valuable 
insight into the workings of ethics within GEL. However, an 
ethnographic analysis would be required to explore the ethi-
cal work conducted within this organisation in more detail, 
and to understand the discursive processes and micro-pol-
itics which shape the ethical debate during group meetings 
(at policy and EAC level), as well as how such processes, in 
turn, influence any ‘digestible output’ which then gets used 
during policymaking (Strassnig 2008). Moreover, further 
work, needs to be conducted to compare those ethical issues 
described by GEL interviewees with the views of health care 
professionals and NHS patients involved with the genomes 
project.
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